Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research report sent to investors on Friday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners initiated coverage on Lipocine in a research report on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price objective on the stock.

Lipocine Trading Up 3.0 %

Shares of Lipocine stock opened at $5.15 on Friday. The company has a 50-day moving average of $5.09 and a 200 day moving average of $5.63. Lipocine has a 1 year low of $2.38 and a 1 year high of $11.79.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter. Equities research analysts forecast that Lipocine will post -0.78 EPS for the current fiscal year.

Hedge Funds Weigh In On Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP purchased a new position in Lipocine Inc. (NASDAQ:LPCN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned 0.22% of Lipocine as of its most recent SEC filing. 9.11% of the stock is owned by hedge funds and other institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.